STOCK TITAN

Squadron funds disclose 6.5% Spruce Biosciences (SPRB) ownership in 13G/A

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Spruce Biosciences investor Squadron Master Fund LP and related parties report beneficial ownership of 70,000 shares of common stock, or 6.5% of the company. This percentage is based on 1,070,370 shares outstanding as of November 7, 2025, as disclosed by Spruce Biosciences.

The stake is held through private funds advised by Squadron Capital Management LLC, an exempt reporting adviser. Squadron, along with partners Matthew Sesterhenn and William Blank, share voting and dispositive power over the 70,000 shares but have no sole authority. They may be deemed beneficial owners yet expressly disclaim beneficial ownership and state the position is held in the ordinary course, without intent to change or influence control.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Squadron Master Fund LP
Signature:/s/ Matthew Sesterhenn
Name/Title:Partner, Squadron Partners LLC, its General Partner
Date:02/17/2026
Squadron Capital Management LLC
Signature:/s/ Matthew Sesterhenn
Name/Title:Partner
Date:02/17/2026
Matthew Sesterhenn
Signature:/s/ Matthew Sesterhenn
Name/Title:Matthew Sesterhenn
Date:02/17/2026
William Blank
Signature:/s/ William Blank
Name/Title:William Blank
Date:02/17/2026

FAQ

What ownership stake in SPRB does Squadron Master Fund report?

Squadron Master Fund LP and related parties report beneficial ownership of 70,000 Spruce Biosciences shares, representing 6.5% of the common stock. This percentage is calculated using 1,070,370 shares outstanding as of November 7, 2025, as reported by the company.

Who are the reporting persons in the Spruce Biosciences (SPRB) Schedule 13G/A?

The filing lists Squadron Master Fund LP, Squadron Capital Management LLC, and individuals Matthew Sesterhenn and William Blank as reporting persons. Squadron Capital Management advises the funds holding the shares, and Sesterhenn and Blank are partners with investment and voting discretion.

How much voting and dispositive power do the Squadron entities have over SPRB shares?

The reporting persons disclose no sole voting or dispositive power, but shared voting and shared dispositive power over 70,000 shares of Spruce Biosciences common stock. All four reporting persons report identical shared voting and dispositive power figures in the ownership breakdown.

On what share count is Squadron’s 6.5% SPRB ownership based?

The 6.5% ownership figure is based on 1,070,370 shares of Spruce Biosciences common stock outstanding as of November 7, 2025. That outstanding share count was reported by Spruce Biosciences in its Form 10-Q filed with the Securities and Exchange Commission.

Do Squadron and its principals claim full beneficial ownership of SPRB shares?

Squadron Capital Management, Matthew Sesterhenn, and William Blank state they may be deemed beneficial owners of all shares held by the funds but expressly disclaim beneficial ownership of the securities, citing Rule 13d-4. The filing clarifies this is not an admission of beneficial ownership.

Is Squadron’s SPRB position intended to influence control of Spruce Biosciences?

The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Spruce Biosciences. It also notes they are not held in connection with any control-related transaction.
Spruce Biosciences, Inc.

NASDAQ:SPRB

SPRB Rankings

SPRB Latest News

SPRB Latest SEC Filings

SPRB Stock Data

70.95M
971.52k
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO